Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is…
$IOVA Hit 52-week highs
@MNGopher63 Follow @MNGopher63 if you are following $IOVa the man taught me everything I know.
1/ The $IOVA calendar from here is stacked: ESMO this week, Oct 23-27 Q3 numbers early Nov Lung trial update in Q4 UK approval decision later this year Switzerland 1H27 EU refile and lung sBLA in 2027
Another 3.2% gain today pushes $IOVA up 126% overall since Aug 6, 2026. Initial tracking on X came from @AviNMash on Aug 6, 2026 at a price of $6.21. Give @AviNMash a follow. Their full record: https://t.co/c5t2j48gQD https://t.co/0lgWG20VZc
$IOVA deep dive live with MN Gopher the man that found this at $2 Join us https://t.co/cIh23B48t9
Since our AI flag on Aug 7 at $6.21, $IOVA has moved up 129%.
10 analysts rate IOVA Buy on consensus.
Consensus price target: $14.40 (+1.84% upside from $14.14)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $263.5M | +60.6% | $-390.98M |
| 2024 | $164.07M | +13698.99% | $-372.18M |
| 2023 | $1.19M | — | $-444.04M |
Stock data for IOVA: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics